Development of Monoclonal Antibody-Based EIA for Tetranor-PGDM which Reflects PGD₂ Production in the Body

Table 2

Analytical recovery of tetranor-PGDM in artificial urine samples with different tetranor-PGDM concentrations.

Concentration (ng/mL)				Mean recoveries (%)
Sample	Spiked	Theoretical	Measured
AU-1 ()	0	—	0.85	—
	0.86	1.32	1.49	113.5
	1.87	2.10	2.09	100.0
	3.91	3.67	3.81	103.8
	9.12	7.68	7.04	93.0
AU-2 ()	0	—	5.95	—
	0.86	5.25	5.53	105.6
	1.87	6.03	6.53	108.4
	3.91	7.60	6.99	91.9
	9.12	11.62	9.53	82.3

Concentration of tetranor-PGDM was 0.85 (AU-1) and 5.95 (AU-2). The theoretical concentrations were corrected using the recovery value from the SPE procedure (77.1% by LC-MS/MS).